Predicting the effects of combining broadly neutralizing ... · Figure 5. Predictions of the...

1
V2 glycan V3 glycan MPER MPER CD4bs Objectives Methods A panel of bNAbs targeting different epitopes were tested in a highly quantitative pseudovirus neutralization assay using TZM-bl target cells [1] on a panel of 199 viral clones. Neutralization curves of 9 different bNAbs (Table 1) in the 0.000128 to 50 ug/mL concentration range were available for analysis. Sigmoidal Emax models were fitted to the data from each bNAb, including between-strain variability (BSV) on E0, IC50, and the Hill factor ɣ. The maximal neutralization was fixed to 1. For combinations of bNAbs, the effects were predicted using the principles of Loewe additivity or Bliss independence [2] and were compared to the observed inhibition in assays using these combinations. From the model, the concentration giving at least 80% inhibition in 80% of viruses types, the IC80(80), was estimated. NONMEM 7.2 with FOCE was used to fit the data. Loewe additivity Loewe additivity assumes that with no synergism or antagonism, one drug can be replaced by an equipotent dose of another. If there is no additional “synergistic” effect when two drugs are combined, the effects of the combination can be predicted by adjusting dose or concentration for potency using Loewe additivity. Predicting the effects of combining broadly neutralizing antibodies (bNAbs) binding to different HIV viral epitopes References 1. Kong, R., Louder, M. K., Wagh, K., Bailer, R. T., deCamp, A., Greene, K., … Mascola, J. R. (2015). Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. Journal of Virology, 89(5), 2659–2671. 2. Berenbaum, M. C. (1989). What is synergy? Pharmacol Rev, 41, 93–141 Per Olsson Gisleskog (1), Mike Seaman (2), Pervin Anklesaria (3), Shasha Jumbe (3) Results (1) SGS Exprimo NV, (2) Beth Israel Deaconess Medical Center-Harvard Medical School, (3) Bill and Melinda Gates Foundation For each bNAb, the inhibition curves varied widely between the virus strains. Notably, some bNabs do not always achieve 100% neutralization even at high concentrations. To fit this wide variability, a mixture model was introduced for IC50, which lead to reasonable fits to the data (Figure 3). Even so, the BSV of IC50 within each mixture subset remained large. Standard errors were generally below 30%, but were usually higher for IC50.2, the IC50 value for the less sensitive subpopulation. For two bNAbs this value had to be fixed to a high value. The values for selected parameters are presented in Table 2. BSV was found to be additive for N0, and exponential for IC50 and ɣ. Residual variability was higher at low neutralization, and was modeled as IC50s generally correlated across strains for bNAbs binding to the same epitope (Figure 2). Predictions using the Bliss independence method agreed better with the observed effect of combinations, than effects predicted using Loewe additivity (Figures 4 and 5). φ was estimated at 0.96 and was not significantly different from 1, indicating that there was no significant synergism or antagonism, but that the bNAbs interacted as described by Bliss independence. Predicted IC80(80) values of selected combinations are shown in Table 3. Conclusions In vitro data of bNAb effects in neutralizing HIV-1 virus showed a highly variable potency between viral strains. Data could be well fitted using sigmoidal Emax models with a mixture model on IC50. When assuming Bliss independence, the model proved predictive for the effects of combinations of bNAbs binding to different viral epitopes. The bNAb combinatorics predictive platform is firmly at the core of data-driven decision- making for the bNAb program, helping to select efficient combinations and dosage regimens. III-38 Promising findings demonstrate that broadly neutralizing antibodies (bNAbs) significantly reduce viral loads in people living with HIV—giving hope for its eventual use in treatment and cure strategies. Numerous highly potent broadly reactive HIV-1- neutralizing antibodies continue to be isolated by different teams. The potency of these antibodies in neutralizing a wide variety of HIV-1 strains is initially explored in-vitro before deciding which molecules progress into optimization and drug development. The objective here was to model the inhibition caused by a range of bNAbs across a panel of 199 clade-C HIV-1 virus strains, using nonlinear mixed effects modelling, and to predict the effects of combining bNAbs binding to different viral epitopes in order to support programmatic decision-making, and selection of suitable combinations and dosage regimens. Figure 1. Observed neutralization vs bNAb concentration, by bNAb type. Each line represents one viral clone. bNAb IC50.1 (μg/mL) IC50.2 (μg/mL) Fr ɣ BSV IC50 (%) IC80(80) (μg/mL) VRC07-523-LS 0.233 25000 (fixed) 5% 1.65 158 3.12 10E8 0.652 69.3 3% 0.96 112 7.21 3BNC117 0.306 75.6 24% 1.09 151 74.8 PGT121 0.118 329 32% 0.98 222 733 10-1074 0.164 468 34% 1.35 213 768 VRC13 0.483 858 24% 0.80 207 788 PGDM1400 0.00725 207 33% 0.63 254 1240 PGT145 0.136 670 34% 0.50 288 7350 CAP256-VRC26.25 0.000151 20000 (fixed) 26% 0.35 389 15800 Figure 3. VPCs of selected models. VRC07 (top left), 10E8 (top right), 3BNC117 (bottom left) and PGT145 (bottom right) Adapted from Burton, Science, 2012 Binding locaBon Binding site bNAb Envelope protein V2 glycan PGDM1400 CAP256-VRC26.25 V3 glycan PGT121 PGT145 10-1074 Top of the trimer MPER 10E8 CD4 binding site CD4bs VRC07-523-LS 3BNC117 VRC13 If Emax A = Emax B and ɣ A = ɣ B (the Hill factor) , the effect of the combination can be predicted by: e.g. if drug A is twice as potent as drug B, 1mg of A will give the same effect as 2mg of B, or as 0.5mg of A + 1 mg of B. Bliss independence Bliss independence predicts effects to be sequential, i.e., the effects are “probabilistically independent”. Using the Emax model, the effect can be calculated from: where φ is a parameter describing any synergism (if φ<1) or antagonism (φ>1). Loewe additivity and Bliss independence give similar but different predictions of the combined effects. C A IC 50, A + C B IC 50, B = 1 E A , B = E max 1 + C A EC 50, A + C B EC 50, B γ 101074 10E8 3BNC117 CAP256VRC2625 PGDM1400 PGT121 PGT145 VRC07523LS VRC13 0.5 0.0 0.5 1.0 0.5 0.0 0.5 1.0 0.5 0.0 0.5 1.0 1e03 1e01 1e+01 1e03 1e01 1e+01 1e03 1e01 1e+01 Concentration (ug/mL) Neutralization Table 1. bNAbs in the modeled dataset. Neutralization i = N 0 i + C γ i i C γ i + IC 50 i γ i i (1 N 0 i ) σ 2 = σ add 2 + σ prop 2 1 Neutralization ( ) Table 2. Selected parameters from the final models. CONC Observations 0.0 0.5 1.0 0.001 0.01 0.1 1 10 CONC Observations 0.5 0.0 0.5 1.0 0.001 0.01 0.1 1 10 CONC Observations 0.5 0.0 0.5 1.0 0.001 0.01 0.1 1 10 100 CONC Observations 0.0 0.5 1.0 0.001 0.01 0.1 1 10 100 1 2 3 4 5 7 8 9 10 11 13 14 15 16 17 19 20 21 22 23 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0.01 1.00 0.01 1.00 0.01 1.00 0.01 1.00 0.01 1.00 Figure 5. Predictions of the combined effects of PGDM1400 and PGT141 on different viral clones, based on individual parameter estimates, compared to the observed effects of the combination. Bliss independence (red) and Loewe additivity (blue). IC50.1: low IC50, IC50.2: high IC50, Fr: proportion of virus strains with high IC50, ɣ: Hill factor, IC80(80): concentration needed to reach 80% neutralization in 80% of viruses. E A , B = 1 1 E maxC A γ ϕ EC 50 A γ C A γ 1 E maxC B γ ϕ EC 50 B γ C B γ Figure 2. log IC50.1 values by virus strain, correlation across bNAbs. V-2 glycans (green), V-3 glycans (blue), CD4bs (orange) and MPER (red) 20 5 5 15 0.087 10 0 5 10 0.75 *** 0.22 ** 5 0 5 10 0.051 0.082 4 0 4 8 0.17 * 10 5 0.026 20 0 15 0.06 0.53 *** 0.23 ** 0.066 0.069 0.12 0.047 ●● ●● ●● ●● ●● 0.12 0.031 0.02 5 5 0.14 * 10 0 10 ●● ●● ●● ●● ●● ●● ●● 0.039 0.057 0.073 0.025 ●● ●● ●● ●● ●● ●● ●● 0.03 0.049 0.055 5 5 0.11 5 5 ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●●● ●● ●● ●● *** ** 0.088 ●● ●● ●● ●●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 4 2 6 0.15 * 4 2 8 ●● ●● ●● ●● ●● ●● ●● ●● ●●● ●● ●● ●● ●● ●● ●● ●● ●● ●●● ●● ●● ●● ●● 0.13 . 10 0 5 ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 5 0 5 ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 5 0 5 10 ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●●● ●● ●● ●● ●● 4 0 4 ●● ●● ●●● ●● ●● ●●● ●● ●● ●● 4 0 2 4 6 4 2 6 0.0 0.2 0.4 0.6 0.8 1.0 0.0 ●●●●●● ●● ●●●●● ●● ●●● ●●● ●●● ●●●●● ●●●● ●●●● ●●●●● ●●● ●●●● ●●●● ●●● ●● ●● ●● ●●● ●●● ●● ●● ●●●●● ●●●● ●●● ●● ●●●●● ●●●● ●●● ●● ●● ●●● ●●● ●●●● ●●●● ●●● ●●●● ●●●● ●●● ●● ●● ●●●● ●●● ●●● ●● ●● ●●● ●●●● ●●●● ●● ●● ●●● ●● ●● ●●●● ●● ●● ●●●● ●●● ●●●● ●●●● ●●●● ●●●● ●● ●● ●●● ●● ●● ●●●● ●●● ●● ●●●● ●●● ●●● ●●●● ●● ●●●● ●●● ●●●● ●● ●●●● ●●● ●●●● ●●● ●●●● ●●●● ●●● ●●●● ●●● ●●●● ● ●● ●●●● ●●●● ●● ●●● ●●● ●●●●● ●●● ●●● ●● ●●●● ●●●● ●● ●●●●● ●●●● ●●●●●● ●●●● ●●● ●● ●●●● ●● ●● ●●● ●●●●● ●●●●● ●●● ●●●● ●●●● ●● ●●●● ●●● ●●●● ●● ●● ●●●● ●●●● ●● ●● ●●● ●● ●●● ●●●●● ●●● ●●●●● ●● ●●●● ●● ●●● ●●●● ●●●●● ●●●● Observations 0.0 0.2 0.4 0.6 0.8 1.0 1.0 ●●●● ●● ●●●● ●● ●● ●●● ●● ●●● ●●●● ●●●● ●●●●● ●●● ●●● ●● ●●● ●● ●● ●● ●●● ●●● ●● ●● ●●● ●●● ●●● ●● ●●●● ●● ●●● ●● ●● ●● ●●● ●●●● ●● ●●● ●●● ●●●● ●●● ●● ●● ●● ●●● ●●● ●● ●●● ●●● ●●● ●● ●● ●●●● ●● ●● ●●●● ●● ●●● ●● ●● ●●●● ●●●● ●●● ●●● ●● ●● ●●● ●● ●● ●●● ●●● ●● ●●● ●● ●●● ●● ●● ●● ●● ●●● ●●● ●● ●●● ●●● ●●● ●●● ●●●● ●● ●●● ●●● ●●● ●● ● ●● ●● ●●● ●● ●●● ●●● ●●●●● ●● ●●● ●● ●●●● ●●● ●● ●● ●●● ●●● ●●● ●● ●●● ●● ●●●● ●● ●● ●● ●●● ●●● ●●●● ●●● ●●● ●● ●● ●●● ●●● ●● ●● ●●● ●●● ●● ●● ●● ●● ●● ●●●● ●●●●● ●●●● ●●● ●● ●●● ●● ●●● ●● ●●● ●●● Figure 4. Predicted vs observed effect of combining PGDM1400 and PGT121 Loewe additivity Bliss independence Predicted from individual parameters of PGDM1400 and PGT121 fits Observed from administering PGDM1400 + PGT121 Two bNAb combinaBons Three bNAb combinaBons bNAb 1 bNAb 2 IC80(80) (μg/mL) bNAb 1 bNAb 2 bNAb 3 IC80(80) (μg/mL) VRC07-523-LS CAP256-VRC26-25 0.856 VRC07-523-LS CAP256-VRC26-25 PGT121 0.483 VRC07-523-LS PGDM1400 1.25 VRC07-523-LS CAP256-VRC26-25 10-1074 0.537 VRC07-523-LS PGT121 1.81 3BNC117 CAP256-VRC26-25 PGT121 0.654 VRC07-523-LS 10-1074 1.96 3BNC117 CAP256-VRC26-25 10-1074 0.726 VRC07-523-LS 10E8 2.02 VRC07-523-LS PGDM1400 PGT121 0.726 PGT121 CAP256-VRC26-25 2.10 VRC07-523-LS 10E8 CAP256-VRC26-25 0.738 3BNC117 CAP256-VRC26-25 2.20 VRC07-523-LS PGDM1400 10-1074 0.807 VRC07-523-LS PGT145 2.28 3BNC117 PGDM1400 PGT121 1.03 10-1074 CAP256-VRC26-25 2.48 VRC07-523-LS 10E8 PGDM1400 1.04 Table 3. Predicted IC80(80) for selected two and three bNAb combinations Concentration (μg/mL) Inhibition *p<0.05, **p<0.01, ***p<0.001

Transcript of Predicting the effects of combining broadly neutralizing ... · Figure 5. Predictions of the...

Page 1: Predicting the effects of combining broadly neutralizing ... · Figure 5. Predictions of the combined effects of PGDM1400 and PGT141 on different viral clones, based on individual

V2 glycan V3 glycan

MPER MPER

CD4bs

Objectives

Methods A panel of bNAbs targeting different epitopes were tested in a highly quantitative pseudovirus neutralization assay using TZM-bl target cells [1] on a panel of 199 viral clones. Neutralization curves of 9 different bNAbs (Table 1) in the 0.000128 to 50 ug/mL concentration range were available for analysis. Sigmoidal Emax models were fitted to the data from each bNAb, including between-strain variability (BSV) on E0, IC50, and the Hill factor ɣ. The maximal neutralization was fixed to 1. For combinations of bNAbs, the effects were predicted using the principles of Loewe additivity or Bliss independence [2] and were compared to the observed inhibition in assays using these combinations. From the model, the concentration giving at least 80% inhibition in 80% of viruses types, the IC80(80), was estimated. NONMEM 7.2 with FOCE was used to fit the data.

Loewe additivity

Loewe additivity assumes that with no synergism or antagonism, one drug can be replaced by an equipotent dose of another. If there is no additional “synergistic” effect when two drugs are combined, the effects of the combination can be predicted by adjusting dose or concentration for potency using Loewe additivity.

Predicting the effects of combining broadly neutralizing antibodies (bNAbs) binding to different HIV viral epitopes

References 1.  Kong, R., Louder, M. K., Wagh, K., Bailer,

R. T., deCamp, A., Greene, K., … Mascola, J. R. (2015). Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. Journal of Virology, 89(5), 2659–2671.

2.  Berenbaum, M. C. (1989). What is synergy? Pharmacol Rev, 41, 93–141

Per Olsson Gisleskog (1), Mike Seaman (2), Pervin Anklesaria (3), Shasha Jumbe (3)

Results

(1) SGS Exprimo NV, (2) Beth Israel Deaconess Medical Center-Harvard Medical School, (3) Bill and Melinda Gates Foundation

For each bNAb, the inhibition curves varied widely between the virus strains. Notably, some bNabs do not always achieve 100% neutralization even at high concentrations. To fit this wide variability, a mixture model was introduced for IC50, which lead to reasonable fits to the data (Figure 3). Even so, the BSV of IC50 within each mixture subset remained large. Standard errors were generally below 30%, but were usually higher for IC50.2, the IC50 value for the less sensitive subpopulation. For two bNAbs this value had to be fixed to a high value. The values for selected parameters are presented in Table 2.

BSV was found to be additive for N0, and exponential for IC50 and ɣ. Residual variability was higher at low neutralization, and was modeled as

IC50s generally correlated across strains for bNAbs binding to the same epitope (Figure 2). Predictions using the Bliss independence method agreed better with the observed effect of combinations, than effects predicted using Loewe additivity (Figures 4 and 5). φ was estimated at 0.96 and was not significantly different from 1, indicating that there was no significant synergism or antagonism, but that the bNAbs interacted as described by Bliss independence. Predicted IC80(80) values of selected combinations are shown in Table 3.

Conclusions •  In vitro data of bNAb effects in neutralizing HIV-1 virus showed a highly variable potency

between viral strains.

•  Data could be well fitted using sigmoidal Emax models with a mixture model on IC50.

•  When assuming Bliss independence, the model proved predictive for the effects of combinations of bNAbs binding to different viral epitopes.

•  The bNAb combinatorics predictive platform is firmly at the core of data-driven decision-making for the bNAb program, helping to select efficient combinations and dosage regimens.

III-38

Promising findings demonstrate that broadly neutralizing antibodies (bNAbs) significantly reduce viral loads in people living with HIV—giving hope for its eventual use in treatment and cure strategies. Numerous highly potent broadly reactive HIV-1-neutralizing antibodies continue to be isolated by different teams. The potency of these antibodies in neutralizing a wide variety of HIV-1 strains is initially explored in-vitro before deciding which molecules

progress into optimization and drug development. The objective here was to model the inhibition caused by a range of bNAbs across a panel of 199 clade-C HIV-1 virus strains, using nonlinear mixed effects modelling, and to predict the effects of combining bNAbs binding to different viral epitopes in order to support programmatic decision-making, and selection of suitable combinations and dosage regimens.

Figure 1. Observed neutralization vs bNAb concentration, by bNAb type. Each line represents one viral clone.

bNAbIC50.1(μg/mL)

IC50.2(μg/mL) Fr ɣ

BSVIC50(%)

IC80(80)(μg/mL)

VRC07-523-LS 0.233 25000(fixed) 5% 1.65 158 3.1210E8 0.652 69.3 3% 0.96 112 7.213BNC117 0.306 75.6 24% 1.09 151 74.8PGT121 0.118 329 32% 0.98 222 73310-1074 0.164 468 34% 1.35 213 768VRC13 0.483 858 24% 0.80 207 788PGDM1400 0.00725 207 33% 0.63 254 1240PGT145 0.136 670 34% 0.50 288 7350CAP256-VRC26.25 0.000151 20000(fixed) 26% 0.35 389 15800

Figure 3. VPCs of selected models. VRC07 (top left), 10E8 (top right), 3BNC117 (bottom left) and PGT145 (bottom right)

Adapted from Burton, Science, 2012

BindinglocaBon Bindingsite bNAb

Envelopeprotein

V2glycan PGDM1400CAP256-VRC26.25

V3glycanPGT121PGT14510-1074

Topofthetrimer MPER 10E8

CD4bindingsite CD4bsVRC07-523-LS3BNC117VRC13

If EmaxA = EmaxB and ɣA = ɣB (the Hill factor) , the effect of the combination can be predicted by:

e.g. if drug A is twice as potent as drug B, 1mg of A will give the same effect as 2mg of B, or as 0.5mg of A + 1 mg of B.

Bliss independence

Bliss independence predicts effects to be sequential, i.e., the effects are “probabilistically independent”. Using the Emax model, the effect can be calculated from:

where φ is a parameter describing any synergism (if φ<1) or antagonism (φ>1).

Loewe additivity and Bliss independence give similar but different predictions of the combined effects.

CA

IC50,A

+ CB

IC50,B

= 1

EA,B =Emax

1+ CA

EC50,A

+ CB

EC50,B

⎛⎝⎜

⎞⎠⎟

γ

10−1074 10E8 3BNC117

CAP256−VRC26−25 PGDM1400 PGT121

PGT145 VRC07−523−LS VRC13

−0.5

0.0

0.5

1.0

−0.5

0.0

0.5

1.0

−0.5

0.0

0.5

1.0

1e−03 1e−01 1e+01 1e−03 1e−01 1e+01 1e−03 1e−01 1e+01Concentration (ug/mL)

Neu

traliz

atio

n

Table 1. bNAbs in the modeled dataset.

Neutralizationi = N0i +

Cγ ii

Cγ i + IC50iγ i

i (1− N0i )

σ 2 =σ add2 +σ prop

2 ⋅ 1− Neutralization( )

Table 2. Selected parameters from the final models. Visual Predictive Check

Observations vs. CONC (Run 614)

CONC

Observation

s

0.0

0.5

1.0

0.001 0.01 0.1 1 10

●● ●

●● ●

●●

● ● ●

●● ●

● ●

● ● ● ●

●● ●

● ● ●

● ●

● ● ● ●

●● ●

● ●

● ●

● ●

●●

● ● ●

● ●

●●

● ●

● ● ●

● ●

● ●

● ● ●

●●

●●

● ●

● ● ●

●● ●

● ● ●

●●

● ● ●

●●

● ● ● ●

● ●

● ●

●●

● ●

● ● ●

●●

● ●

● ●

● ●

● ● ●

● ● ●

●● ●

●●

●● ●

●● ●

● ●

● ●

●● ●

● ●

● ● ● ●

● ●

● ●

● ● ●

●●

●●

● ● ●

●●

● ●

●●

● ●

●● ●

●● ●

● ● ●

● ●

● ● ●

● ● ●

● ● ●

● ●

● ●

● ● ●

● ●

●●

● ● ●

●● ●

●● ●

● ●

●● ● ●

● ●

● ●

●● ● ●

● ●

● ●

●●

● ● ●

●●

● ● ● ●

●● ● ●

● ●

● ●

● ●

● ●

●●

●●

● ● ●

●● ●

● ● ●

● ● ●

●●

● ● ●

● ● ● ●

● ●

●●

●●

● ●

●●

● ●

●● ● ●

● ●

● ● ●

●● ●

● ●

● ● ●

● ●●

● ● ●

● ● ●

● ●

● ●

● ●

●●

● ● ●

●●

●●

● ●

●● ●

●●

● ●

● ●

● ●

● ● ●

● ●

●● ●

● ●●

●● ● ●

● ●

● ● ●

● ● ●

● ●

● ●

● ●

● ●

● ●

● ●

● ●

● ● ●

● ● ●

● ●

●● ●

● ● ●

● ● ●

●●

● ●

● ● ●

● ●

● ● ●

● ●

● ●

● ●

● ●

● ●

●● ●

● ●

● ●

● ● ● ●

● ●

●●

● ●

● ●

● ●

● ● ●

● ● ●

● ●

● ●

● ●

●●

● ● ●

●●

●●

●● ●

● ●

●●

● ●

●● ●

● ●

●●

●●

●● ● ●

● ● ●

●● ●

● ●

● ●

● ● ●

●● ●

● ● ●

● ● ●

● ●

● ● ●

Visual Predictive CheckObservations vs. CONC (Run 590)

CONC

Observation

s

−0.5

0.0

0.5

1.0

0.001 0.01 0.1 1 10

●●

●●

● ●

● ●

●●

●●

●●

●●

●●●

●●●

●●

●●

●●

● ●

●●

● ●

●●

● ●

●●

●●

●●

● ●

●●

●●●

● ●

● ●

●●

●●

●●

● ●

● ● ●

● ●

●●

● ●

● ●

● ●

●●

● ●

●●

●●

●●

●●

● ●

● ●

●●

●●

●●

● ●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

● ●

● ●

● ●

● ●

● ●

● ●

● ●

●●

●●

●●

●●

● ●

● ●

● ●

●●

● ●

● ●

●● ●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●●

●●●

●●●

●●

●●

●●

●●●●

●●●

●●

●●●

●●●

●●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●●

● ●

●●

● ●

●●

●●

●●●

●●● ●●●

● ●

●●

● ●

●●

● ●

●●

● ●

●●

●●

●●

●●

●●●

●●● ●●●

●●

●●

●●

●● ●●●

●●

● ●●●

●●

●●

● ● ●

●●

●●

● ●

● ● ●

●●

● ●

●●●

●●

●●●

●●

●●

●●

●●

●●●

●●●

●●●

●●

●●

●●●

●●●●●●

●●

●●

●●●

● ●

●●

●●●

●●●

●●

●●

●●

●●●

●●

●●●

●●

●●●

●●

Visual Predictive CheckObservations vs. CONC (Run 586)

CONC

Observation

s

−0.5

0.0

0.5

1.0

0.001 0.01 0.1 1 10 100

● ●

●●

●●

●●

● ●

● ●

●●

● ● ● ●

●●

● ●

● ● ●

●●

●●

●●

●● ● ●

●● ●

● ●

● ●

● ●

●●

●●

● ●●

● ●

● ●

● ●

● ●

● ●

●●

●●

●●

●●

●●

●●

●●

● ●●

● ●

● ●

●●

●●

●●

●● ●

● ●

●●

●●

●●

●●

● ●

●●

● ●

● ●

●●

●●

●●

● ●

● ●

●● ●

● ●

● ●

● ●

● ● ●

●●

● ● ●

●●

●●

●●

● ●

● ●

● ● ●

●● ●

●●

●●

● ●●

●●

●●

●● ●

● ● ●

●●

● ●

●● ● ●

●●

● ● ●

●● ●

●● ●

● ●

●●

●●

● ●

● ●

●●

●●

● ●

●●

●●

● ●

●●

● ● ● ● ● ●

●●

● ●

●●

●● ●

● ● ●

●●

● ● ●

● ●

● ● ●

● ●

●●

●●

● ● ●

● ●

● ●

●●

● ●

●●

●●

●●

●●

●●

● ●

●●

●●

●●

● ●

● ●

● ●

●●

● ●

● ●

● ● ●

●●

●●

● ●

● ●

●●

●●

● ●

● ●

●● ● ●

●● ●

●●

●●

● ●

● ● ● ● ● ●

●●

● ● ● ●

● ●● ● ● ●

●● ●

●●

●●

● ● ● ●

●● ● ● ● ●

●● ●

●●

● ● ● ●

● ●●

●●

●●

● ●

●●

●●

● ●● ●

●●

● ● ●

● ●

●●

● ● ● ●

● ●

● ●

●●

● ●

● ●

● ●

●●

●● ● ●

● ●●

●● ● ●

● ●

● ●

● ● ●

●●

●●

●●

●●

●●

●●

●●

● ●

● ●

●●

● ● ● ● ●

●●

●●

●●

● ●

● ●

●●

● ●

●●

● ● ●

●●

● ●

●●

● ● ●

●●

●●

● ●

●●

● ●

● ●

● ●

● ● ●

● ●

● ●

●●

●●

●●

● ● ● ● ●

●●

● ● ●

● ●

●●

● ● ●

● ● ●

● ●

●●

● ● ●

● ●

●●

● ●

●●

●●

● ● ●

●●

●● ●

●●

● ●

●●

● ●

Visual Predictive CheckObservations vs. CONC (Run 591)

CONC

Observation

s

0.0

0.5

1.0

0.001 0.01 0.1 1 10 100

●●

● ● ●

●● ●

● ●

●●

● ●

●●

●●

●●

● ●

●●

●●

● ●

●●

●●

● ●

●●

● ●

● ●●

●● ●

●● ●

●● ●

● ●

●●

● ●

●●

● ●

● ●

●●

● ●

●●

●● ●

● ●

●●

●●

● ●

●● ● ●

●●

● ●

●●

● ●

●●

●●

● ●

●●

●●

● ●

●●

●●

● ●

●●

● ●●

● ●

●●

●●

●●

● ●●

● ●

● ●

● ●●

● ●

●●

●●

●●

● ●●

●●

● ●●

●●

●●

●●

● ●

●●

●●

●●

● ●

●● ●

●●

● ●

●● ●

●● ● ●

●●

●●

●●

●●

● ●

●●

●●

● ●

● ●

●●

●●

●●

● ●

●●

● ●

● ●

●●

●●

● ●

●●

● ●

●●

●●

● ●

●●

●●

●●

● ●

●●

● ●

● ●

●●

●●

●●

●●

● ●

●●

● ●

●●

●●

●●

● ●

●● ●

●●

● ●

●●

●●

● ●●

●●

● ● ●

●●

●●

●●

● ●

● ●

●●

● ●●

●●

●● ● ●

●●

●●

● ●

● ●

●● ● ● ● ● ●

●● ● ●

● ● ● ● ●

● ●

●●

●● ●

● ●

● ●

●●

● ● ● ● ●

●● ● ● ● ●

●●

● ● ● ●

●● ● ● ● ● ●

●● ● ● ●

●● ● ● ● ● ●

●● ● ● ● ●

●● ● ● ●

● ● ● ● ●

● ● ● ● ● ●

● ● ● ●

● ●●

●●

●● ●

●●

●● ●

● ●

●●

● ●

● ●

1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

0.00

0.25

0.50

0.75

1.00

0.00

0.25

0.50

0.75

1.00

0.00

0.25

0.50

0.75

1.00

0.00

0.25

0.50

0.75

1.00

0.01 1.00 0.01 1.00 0.01 1.00 0.01 1.00 0.01 1.00 0.01 1.00Con

DV

Figure 5. Predictions of the combined effects of PGDM1400 and PGT141 on different viral clones, based on individual parameter estimates, compared to the observed effects of the combination. Bliss independence (red) and Loewe additivity (blue).

IC50.1: low IC50, IC50.2: high IC50, Fr: proportion of virus strains with high IC50, ɣ: Hill factor, IC80(80): concentration needed to reach 80% neutralization in 80% of viruses.

EA,B = 1− 1−Emax⋅C

A

γ

ϕ ⋅EC50Aγ ⋅C

A

γ

⎝⎜⎞

⎠⎟1−

Emax⋅CB

γ

ϕ ⋅EC50Bγ ⋅C

B

γ

⎝⎜⎞

⎠⎟

Figure 2. log IC50.1 values by virus strain, correlation across bNAbs. V-2 glycans (green), V-3 glycans (blue), CD4bs (orange) and MPER (red)

x

Den

sity PGDM1400

−20 −5 5 15

0.74*** −0.087

−10 0 5 10

0.75*** −0.22**−5 0 5 10

0.051

0.082

−4 0 4 8

0.17 *

−10

5

0.026

−20

015

● ●●

●●●

● ●●

●●●● ●

●●

●● ●

●● ●

●● ●●

●●

●●

●● ●●●●

●●

● ●●● ●●●

● ●

●●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●● ●●●

●●

●●●

●●

●●●●

●●●

●● ●●●●

●●●●

●●

●●

● ●

●●

●●●

●●

●●● ●

●●●

● ●●

●●

●●

●●●

●●●

●●●

● ●

x

Den

sity CAP256

−0.06

0.53*** −0.23** 0.066

0.069

0.12

0.047

●●

●●

●●

●●●

● ●

●●

●●●

●● ●

●●

●●

●●

● ●●●

●●

●●

●●

●●●

● ●●

● ●

● ●●

●●●●

●● ●

●● ●

●●

●●

●●●

●●

●●

●●●● ● ●

●●●●

● ●

● ●●

●●●

● ●

●●

●●

●●

● ●

●●

●●●●

●●

●●

●●

●●

●●

●●

● ●

●●

●●

●● ●

●●

● ●

●●

● ●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●●

●●

●●

●●

● ●●●●

●●

●●

●●

●●●

●●●

● ●

● ●●

●●●●

●● ●

●● ●

●●

● ●

●●●

●●

●●

●●●● ● ●

●●● ●

●●

● ●●

● ●●

●●

●●

●●

●●

● ●

●●

●●● ●

● ●

●●

●●

●●

●●

●●

● ●

●●

● ●

●● ●

●●

● ●

●●

●●●

●●

●●

●●

●●

x

Den

sity PGT121

−0.029

0.79*** 0.12

0.031

0.02

−55

0.14 *

−10

010

●●●

●●●●

●●

●●

●●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

● ●●● ●

●●

●●●

●●

● ●● ●

●●●

●●

●● ●

● ●

●●

●●●●

●●

●●

●●

●●

●●●

● ●●

●●

●●●●● ●

●●

●●

●●

●●●

●●

●●

● ●●

●●

●●

●●

●●● ●

●●●

● ●●●

●●

●●●

● ●●

●●

● ●

●●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●●

●●

● ● ●● ●

● ●

●●●

●●

● ●● ●●●

●●

●●●● ●

● ●

●●●●

●●

●●

●●

●●

●●●●●●

●●

●●●●● ●

●●

●●

●●

●●

●●

●●

●● ●

●●

●●

●●

●● ●●

●●●

●● ●●

●●

●●

● ●●

●●

●●

●●●

●●

●●●

●●

●●

●●

●●

● ●

●●

●●

●●●

●●

●●●●●

●●

●● ●

●●

● ●●●●●●

●●

●●●

● ●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●●

●●

● ●●●● ●

●●

●●

● ●

●●

●●

●●

●●●

●●

●●

● ●

●●● ●

x

Den

sity PGT145

−0.10

0.039

0.057

0.073

0.025

● ●

●●●

●●

● ●● ●●

● ●

●●

● ●

●●

●●

●●

●●●

●●

● ●

●●

●●

●●

●●●

●●

●●

●●●●

● ● ●

●●●

●●●●

●●

●●

● ●●

●●

●●

●●● ●

● ●

● ●

●●

●●●●

●●

●●

● ●

●●

●●●

● ●

●●

●●●

●●●

●●●

●●● ●

●●

● ●

●●

●●

●●

●●

●●

●● ●

●●

●●

●● ●

●●

● ●●●

●●

●●

● ●

●●

●●

●●

●●●

●●

●●

●●

●●

●●●●●

●●

●●

●●●●

●● ●

●●●

● ●●●

●●

●●

● ●●

●●

●●

●● ●●

● ●

● ●

●●

●●● ●

● ●

●●

● ●

●●

●●●

● ●

●●●

●●

●● ●

●●●

●●● ●

●●

●●

●●

●●

●●

●●

●●

●● ●

●●

● ●

●●●

●●

●●● ●●

●●

●●

● ●

●●

●●

●●

●●●

●●

● ●

●●

●●

●●

●●●

●●

●●

●●

●●

● ●●

●●●

●● ●●

●●

●●

●●●●

●●

●●

●●●●

● ●

●●

●●

●●●●

●●

●●

●●

●●

● ●●

● ●

●●

●● ●

●●●

●●●

●●●●

●●

●●

●●

●●

●●

●●

●●

● ●●

●●

● ●

●●●

●●

● ●● ●●

● ●

●●

● ●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●●●

● ●●

●●●

●●●●

●●

●●

●●●●

●●

●●

●●● ●

● ●

● ●

● ●

●● ● ●

●●

● ●

●●

●●

●●●

● ●

●●

●●●

●●●

●●●

●●● ●

●●

● ●

●●

●●

●●

●●

●●

●● ●

●●

x

Den

sity _10.1074

0.03

−0.049

−0.055

−55

0.11

−55

● ●●●

●●●

●●

●●● ● ●

●●

●●●

●●

●●

●●●●

●●●

●● ●●

●● ●●

● ●●● ●●● ●●

●●●

●●●

●●●

●●●●●

●●

●● ●

●●

●●●

●● ●

●●

● ●●●

●●●●

●● ● ●

●●

●●

●●

●● ● ●●● ●●

● ●●●

●●●●

●●●

●●● ●

●●

●●●

●●

● ●

●●

● ●●

●●●●

●●

●● ●●●●

●● ●●

● ●

●●

●● ●●

● ●● ●

●● ●● ●●● ●●●

● ●●●●

●●●

●●

●●● ●●●●

●●●

●●●

●●

●●

●●●

● ●●●

●● ●●

●●●●●●●

●●

●●●

●●

●● ●

●●●●●●●

●● ●

●●

●● ●

●● ●●

● ●●●

●●●●

● ● ● ●

●●

●●

●●

●● ● ●●● ●●

● ●●●

●● ●●

●●●

●●● ●●

●●●

●●

● ●

●●

● ●●

● ●●●

●●

●● ●●● ●

● ●●●

●●

●●

●● ●●● ●

● ●

●● ●●●●● ●●●● ● ●●

●●

● ●

●●

●●● ●●

●●

●●●●

●●●

●●

● ●

●●●●

● ● ●●

●● ●●●● ●●●●●

●●

●●●

●●

●●●●

●●● ●●● ●

●●●

●●

●●●

●●●

●●

●●●●

●●●●●

●● ●●

●●

●●

●●

● ●● ● ●●● ●

● ●●●

●●●●●●

●● ●● ●

●●

●●●

●●

● ●

●●

●●●●●●

●●

●● ● ●●● ●

●●●●

●●

●●

●●●●

●●●●

● ●● ●●● ●● ●●

● ● ●●●

●●●

●●

●●● ● ●

● ●

●●●

●●

●●

●●

●●

● ●●

●●●●

●● ●●

●● ●● ●●● ●●

●●●

●●

●● ●

●●●● ●●●

●●●

●●

●●●

●● ●

●●

●●●●

●●●●

● ●● ●

●●

●●

●●

●● ● ●●● ●●

●●● ●

●●●●

● ●●

● ●● ●●

●●●●●

● ●

●●

● ●●

●● ●●

●●

●● ●●● ●

●● ●●

● ●

●●

●● ●●● ●● ●

●● ●● ●●● ●●●● ●●●

●●● ●

●●●

●●● ●●●●

●● ●

●●

●●

●●

● ●

●●●

● ●●●

●● ●●●●●● ●●

●●

●●●

●●

●●●●

●●● ● ●

● ●

●●●

●●

●●●

●●●

●●

●● ●●

●●●●

●● ●●

●●

●●

●●

● ●●● ●●● ●

● ●●●

●●●●

●●●

● ●●●

●●

● ●●

●●

●●

●●

●●●

●●●●●●

● ●●●● ●

●●●●

●●

●●

●●●●

●●●●

● ●● ●●●●● ●●

x

Den

sity VRC07

0.49*** 0.19** 0.088

●●

●●

●●

● ●●●

● ●

●●●

●●

●●

●● ●

●●● ●●

●●●

●●

●●

●●●

●● ●●

●●●●

●●

●●

● ●

●●

●●

●●

● ●

●●

●●●

●●●

●●

● ●

●●

●●

●●●

●●●

●●

●●

●●

●●●

●●●●

●●

●●

● ●●

●●●●

●●●●

●●

●●

●●●●

●●

●●●●●

●●

●●

●●● ●

● ●●

●●

● ●

●●

●●

●●

● ●● ●

● ●

●●●

●●

●●

●● ●

●●● ●●

●●●

●●

●●

●●●

●● ●●

●●●●

●●

● ●

● ●

● ●

● ●

●●

● ●

●●

●●●

●●●

● ●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●●

●● ●●

●●

●●

●●●

●●●●

●●●●

●●

●●

●●●

●● ●

●●● ●●

●●

●●

●●● ●●●

●●● ●

●●

●●

●●

● ●● ●

●●

●●●

●●

● ●

●● ●

●●●●●

●●●

●●

●●

●● ●

●●●●

●●●●

●●

●●

●●

●●

●●

●●

● ●

● ●

●●●

●●●

●●

●●

●●●

●●

● ●●

●●●

● ●

● ●

●●

●●●●

●●●

●●

●●

●●●

●●●

● ●●●

●●

●●

●●●

●●●

●●● ●●

●●

●●

●● ●●

●●●

●●

● ●

●●

●●

● ●

● ●●●

● ●

●● ●

●●

●●

●● ●

●●● ●●

●●●

●●

●●

●●●

●● ●●

●●●

●●

●●

●●

●●

●●

●●

● ●

● ●

●●●

●●●

●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●●

●●●

●●●

●●●

●●●

●●●●

●●

●●

●●●

●●●

●●● ●●

●●

●●

●●● ●

● ●●

●●● ●

●●

●●

●●

●●●●

●●

●● ●

●●

●●

●● ●

●● ●●●

●●●

●●

●●

●● ●

●●●●

●●●

●●

●●

●●

●●

●●

● ●

● ●

● ●

● ●●

●●●

●●

● ●

●●

●●

●●●

●●●

● ●

● ●

●●

●●●●

●●●

●●

●●

● ●●

●●●

●● ●●

●●

●●

●●●

●●●

●● ● ●●

●●

●●

●● ●●

●●●

●●

● ●

●●

●●

●●

●●●●

●●

●● ●

●●

●●

●● ●

●●●●●

●●●

●●

●●

●●●

●● ●●

●●●●●

●●

●●

● ●

●●

● ●

●●

●●

●●●

●●●

● ●

●●

●●

●●

●●●

●● ●

●●

●●

●●

●●●

●●●●

●●●

●●●

●●●

●●●●

●●

●●●●

●●●●

●●● ● ●

●●

●●

●●●●

●●●

●●

x

Den

sity _3BNC117

0.41***

−42

6

0.15 *

−42

8

●●

●●● ●

●●

●●

●●

●●

●●

● ●●● ●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●●

●●

● ●● ●

● ●

●●

●●

●●

●●

● ●●

●● ●

● ●●●●●

●●

●●

●●

●●

●● ●

●●

●●●●

●●

● ●●

●●

● ●

●●

●● ●

●●

● ●

● ●●

●● ● ●

●●

●●● ●●

●●

●●

●●

● ●

●●

●●●● ●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●●●

●●

● ●● ●

● ●

●●

● ●

●●

●●

●●●

●● ●

● ●●●●●

●●

●●

●●

●●

●● ●

●●

●●● ●

●●

● ● ●

●●

●●

●●

●● ●

●●

● ●

●●●

●●● ●

●●

●●●

●●

●●

●●

●●

●●

●●

●●● ●●

●●

●● ●

●●

●●

●● ●

●●

●●

●●

●●

●● ●●

●●

● ● ●●

●●

●●

●●

●●●

●●

●●●

●●●

● ●●●●●

●●

●●

●●

● ●

●● ●

● ●

●●●●

●●

●● ●

●●

●●

●●

●●●

●●

●●

●●●

●● ● ●

●●

●●● ●

●●

●●

●●

●●

●●

● ●●● ●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●●

●●

●● ●●

●●

●●

●●

●●

●●

● ●●

●● ●

●●● ●●●

●●

●●

●●

●●

●● ●

●●

●●●●

●●

● ● ●

●●

● ●

●●

●● ●

●●

● ●

● ●●

●●● ●

●●

●●●

●●

●●

●●

●●

●●

●●

● ●● ●●

●●

●● ●

●●

●●

●● ●

●●

●●

●●

●●

●● ●●

●●

● ● ●●

●●

●●

●●

●●

●●

●●●

●●●

● ●●●●●

●●

●●

●●

●●

●●●

● ●

●● ●●

●●●● ●

●●

●●

●●

●●●

●●

●●

●●●●

●●● ●

●●

●●●●●

●●

●●●

●●

●●

●●

●●●●●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●●●

●●

● ●●●

● ●

●●

● ●

●●

●●

● ●●

●●●●

●●●●●●

●●

●●

●●

●●

●●●

● ●

●●●●

●●●●●

●●

●●

●●

●●●

●●●

●●

●●●●

●●● ●

●●

●● ●●

●●

●●

●●

● ●

●●

● ●● ●●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●●

●●

● ●●●

● ●

●●

●●

●●

●●

● ●●

●● ●

●●● ●●●

●●

●●

●●

●●

●●●

● ●

●●●●

●●●● ●

●●

●●

●●●

●●

●●

●●

●●●

●●●

x

Den

sity VRC13

0.13.

−10 0 5

● ●● ●●

●●● ●● ●

● ●●●●●

● ●

●●●●●

●●

●● ●

●●● ●● ●

●●●

●●● ●●

●●

●●

●●●●

●●

●●● ●

●●

● ●

●●

●●

● ●

●● ●●

●●

● ●● ●

● ●● ●● ●●● ● ●

●●

●●●

●●● ●

●●●

●● ●●●

●●

●●● ●●●●●●

●●●●

● ●●

●●

● ●

● ● ●●●●

●●●●●

●● ●●●

●●

● ●

●●

● ●●

● ●●

●●

●●● ●●

●●

●●●

●●

●●● ●

●●● ●●

●●● ●

●●

● ●● ●

●●

●●

●●●● ●

●●●

●● ●

●●● ● ●●

●●●

●●●●●

●●

●●

●●●●●

●● ●

● ●

●●

● ●

●●

● ●

● ●

●● ●

●●

● ●● ●

● ●● ●● ●●

● ● ●●

●● ●

● ●● ●

●● ●●

●●●●

●●

●●● ●●●

● ●●●

●●

●●●

●●●●

●● ●● ●●

●●●● ●

●● ●●●

●●

● ●

●●

● ● ●

●●●

●●

●●● ●●●

●●

●●●

●●

●●●●

−5 0 5

● ●●●●

●●●●

● ●

● ●●●

●●

● ●

● ●●●●

●●●

●●●●

●●● ● ● ●

●●●

●●●●●

●●

●●

●● ●●

●●

●●●●

●●

●●

●●●●

●●

●●●

●●●● ●●

● ●● ●●●●●●●

●●

●●●

●●●●

●●●

●●●

●●

●●

● ●●● ●●

● ●●●●●●

● ●●

●●

●●

●● ●● ● ●

●●●

● ●

●●● ●●

●●

●●

●●

●●●

●●●

●●

●●●●●

●●

●● ●

●●

● ●● ●

● ●● ●●

●●● ●● ●

● ●●●

●●

● ●

●● ●●●

●●

●● ●

●●● ●●●

●●●

●●●●●

●●

●●

●● ●●

●●

● ●● ●

●●

● ●

●●●●

●●

●● ●●

●●

● ●● ●

● ●●●●●●

●● ●●

●●●

● ●● ●

●●●

●● ● ●●

●●

●●● ● ●●

●● ●●

●●

●● ●

●●

●●

●● ●● ●●

●●●

● ●

●● ●●●

●●

●●

●●

● ● ●

● ●●

●●

●●● ●●●

●●

●●●

●●

●●●●

−5 0 5 10

●●●●●

● ●●●

●●

● ●●●

●●

● ●

● ● ●●●

●●

●●●

●●● ● ●●

●●●● ●●●

●●

●●

●● ●●

●●

●●●●

●●

●●

●●●●

●●

●●●●

●●

●● ●●

● ●● ●●● ●

●● ●●

●●●●

●●●●

●● ●●

●●●●

●●● ●●● ●

●●●●●

●●●

● ●●

●●

●●

● ●●● ●●

●●●

● ●

●●●● ●

●●●●

●●●●

●●●

●●

●●●●●

●●

●● ●

●●● ●

●●●●● ●●

● ●● ●

● ●

●●● ●

●●●

● ●

● ● ●●●

●●

●●●

●●● ●●

●●●

● ●●●●

●●

●●

●●●●

●●

●●● ●

●●

●●

●●

●●

●●

●● ●

●●

●●● ●

●● ● ●●●●

● ●●●●

● ●●

●●●●

●●●

●● ●● ●

●●●●●●●

●● ●●●

●●

●● ●●

●●●●

●●● ● ●●

●●●

● ●

●●●●●

●●

●●

●●●●●

●●●

●●

● ●●●●●

●●

●●●

●●

●●●●

−4 0 4

● ●● ●●

● ●●●

● ●

●●● ●

●●●

● ●

● ●●● ●

●●

●●●

●●●●●●

●●●

●●●●●

●●

●●

●●●●

●●● ●

●●

●●

● ●

●●

●●

●●

●● ●

●●● ●● ●

●●● ●●●●

● ●●●●

●●●

●●●●

●●●

●● ●●●

●●

●● ●●●●

● ●●●●

●●

● ●●

●●

● ●

●●●● ●●

●●●

● ●

●●●●●

●●

●●

●●●● ●

● ●●

●●

●●●●●

●●

●● ●

●●

●●●●

● ●● ●●

●●● ●

● ●

●●● ●

●●

●●

● ●●● ●

●●

●●●

●● ●● ●●

●●●

●●● ●●

●●

●●

●●●●●

●● ●

● ●

●●

●●

●●

● ●

● ●

●● ●

●●

●●●●

●●●●●● ●

●●●●●

●●●

●●● ●

●● ●

●●●

● ●

●●

●● ●●●●

● ●●●●●

●● ●

●●

● ●

● ●● ●●●

●●●

● ●

●●●●●

●●

●●

●●

●●●

●●●

●●

● ●●● ●

●●

●●●

●●

●●●●

−4 0 2 4 6

−42

6

x

Den

sity _10E8

Observations vs. Population predictions (Run 233)[TMT==3]

Population predictions

Obs

erva

tions

0.0

0.2

0.4

0.6

0.8

1.0

0.2 0.4 0.6 0.8 1.0

● ●●●●●

●●●

● ●●●●

●●

●●

● ●

●●

●●●

●●●●

● ●●●

●●●●●●

● ●●●

●●●●●●

●●●●●

●●●●

●●●●

●●●●●

●●●●

●●

●●

●●

●●

●●

●●●

●●

●●●●●

●●●●

●●

●●●

●●●

● ●●●●

●●●●●

●●●●

●● ●

●●●●●

● ●●●●●

●●

● ●●

● ●

●●●

●●

●●●●●

●●

●●

●●

● ●●

● ●●●

●●●●●

●●●

●●●●

●●●●

●●●

●●

●●

● ●

●●●●●

●●●●

● ●●

●●

● ●

●●●

●●●●●

● ●●●●

●●●●

●●

●●

●●

●●

● ●●●

●●

●●●

●●●●●

●●●●●●

●●

●●●●●

● ●●●

●●●●●

●●●●

●●●●

● ●●●●

●●

● ●

●●●

●●●●

● ●

● ●●

●●●●●

●●●●

●●●

● ●●●

● ●

●●●●

● ●

●●

●●●

●●●●●

●● ●

●●●●●

●●●●●

●●●●

●●

●●

●●●●

● ●●●

●●●●

●●

●●

●●

● ●●●●

● ●●

● ●●●●

●●●●●

●●

●●●●

●●●●●

●●

● ●●

●●●●

●●●●●

● ● ● ● ●

●●●●

● ●●●

●●

●●●●●

●●●●●

● ●●●●

●●

●●●●●

●●●●

● ●

● ●●

●●●●●

●●

●●

●● ●●●

●●●●

●●

● ●

● ●●●●

●●

●●●●

● ●●●●●

● ●●●●

●●●

●● ●

● ●●●

● ●

●●●●

●●●●●

● ●●●●

●●●●●●

● ● ●●

●●●●

●●●●

●●

●●

●●

●●●●●●

●●●●

● ●●●●

●●●●●

●●●●●

●●●●

●●

●●●

●●●

● ●

● ●

● ●●●

●●●●●●

● ●●●

●●●●●

●●

●●

●●

●●

● ●●●

●●●●●

●●●●

●●●●●●

● ●●●

Observations vs. Individual predictions (Run 233)[TMT==3]

Individual predictions

Obs

erva

tions

0.0

0.2

0.4

0.6

0.8

1.0

0.0 0.2 0.4 0.6 0.8 1.0

●●●●●●

●●●

●●●●●

●●

●●

● ●

●●

●●●

●●●●

● ●●●

●●●●●●

●●●●

●●●●●●

●●●●●

●●●●

●●●●

●●●●●

●●●●

●●

●●

●●

●●

●●

●●●

●●

●●●●●

●●●●

●●

●●●

●●●

● ●●●●

●●●●●

●●●●

●●●

●●●●●

●●●●●●

●●

●●●

● ●

●●●

●●

●●●●●

●●

●●

●●

●●●

●●●●

●●●●●

●●●

●●●●

●●●●

●●●

●●

●●

●●

●●●●●

●●●●

●●●

●●

● ●

●●●

●●●●●

● ●●●●

●●●●

●●

●●

●●

●●

● ●●●

●●

●●●

●●●●●

●●●●●●

●●

●●●●●

●●●●

●●●●●

●●●●

●●●●

●●●●●

●●

● ●

●●●

●●●●

● ●

● ●●

●●●●●

●●●●

●●●

● ●●●

● ●

●●●●

● ●

●●

●●●

●●●●●

●●●

●●●●●

●●●●●

●●●●

●●

●●

●●●●

●●●●

●●●●

●●

●●

●●

●●●●●

● ●●

●●●●●

●●●●●

●●

●●●●

●●●●●

●●

● ●●

●●●●

●●●●●

● ● ● ●●

●●●●

● ●●●

●●

●●●●●

●●●●●

● ●●●●

●●

●●●●●

●●●●

● ●

●●●

●●●●●

●●

●●

●●●●●

●●●●

●●

● ●

● ●●●●

●●

●●●●

●●●●●●

● ●●●●

●●●

●● ●

● ●●●

●●

●●●●

●●●●●

● ●●●●

●●●●●●

● ●●●

●●●●

●●●●

●●

●●

●●

●●●●●●

●●●●

● ●●●●

●●●●●

●●●●●

●●●●

●●

●●●

●●●

●●

● ●

● ●●●

●●●●●●

● ●●●

●●●●●

●●

●●

●●

●●

●●●●

●●●●●

●●●●

●●●●●●

● ●●●

Observations vs. Population predictions (Run 236)[TMT==3]

Population predictions

Obs

erva

tions

0.0

0.2

0.4

0.6

0.8

1.0

0.2 0.4 0.6 0.8 1.0

●●●●●●

●●●

●●●●●

●●

●●

●●

●●

●●●

●●●●

●●●●

●●●●●●

●●●●

●●●●●●

●●●●●

●●●●

●●●●

●●●●●

●●●●

●●

●●

●●

●●

●●

●●●

●●

●●●●●

●●●●

●●

●●●

●●●

●●●●●

●●●●●

●●●●

●●●

●●●●●

●●●●●●

●●

●●●

●●

●●●

●●

●●●●●

●●

●●

●●

●●●

●●●●

●●●●●

●●●

●●●●

●●●●

●●●

●●

●●

●●

●●●●●

●●●●

●●●

●●

● ●

●●●

●●●●●

●●●●●

●●●●

●●

●●

●●

●●

●●●●

●●

●●●

●●●●●

●●●

●●●

●●

●●●●●

●●●●

●●●●●

●●●●

●●●●

●●●●●

●●

●●

●●●

●●●●

●●

●●●

●●●●●

●●●●

●●●

●●●●

●●

●●●●

● ●

●●

●●●

●●●●●

●●●

●●●●●

●●●●●

●●●●

●●

●●

●●●●

●●●●

●●●●

●●

●●

●●

●●●●●

●●●

●●●●●

●●●●●

●●

●●●●

●●●●●

●●

●●●

●●●●

●●●●●

● ● ● ●●

●●●●

●●●●

●●

●●●●●

●●●●●

●●●●●

●●

●●●●●

●●●●

●●

●●●

●●●●●

●●

●●

●●●●●

●●●●

● ●

●●

●●●●●

●●

●●●●

●●●●●●

●●●●●

●●●

●●●

●●●●

●●

●●●●

●●●●●

●●●●●

●●●●●●

●●●●

●●●●

●●●●

●●

●●

●●

●●●●●●

●●●●

●●●●●

●●●●●

●●●●●

●●●●

●●

●●●

●●●

● ●

●●

●●●●

●●●●●●

●●●●

●●●●●

●●

●●

●●

●●

●●●●

● ●●●●

●●●●

●●●●●●

●●●●

Observations vs. Individual predictions (Run 236)[TMT==3]

Individual predictions

Obs

erva

tions

0.0

0.2

0.4

0.6

0.8

1.0

0.0 0.2 0.4 0.6 0.8 1.0

●●●●●●

●●●

●●●●●

●●

●●

●●

●●

●●●

●●●●

●●●●

●●●●●●

●●●●

●●●●●●

●●●●●

●●●●

●●●●

●●●●●

●●●●

●●

●●

●●

●●

●●

●●●

●●

●●●●●

●●●●

●●

●●●

●●●

●●●●●

●●●●●

●●●●

●●●

●●●●●

●●●●●●

●●

●●●

●●

●●●

●●

●●●●●

●●

●●

●●

●●●

●●●●

●●●●●

●●●

●●●●

●●●●

●●●

●●

●●

●●

●●●●●

●●●●

●●●

●●

● ●

●●●

●●●●●

●●●●●

●●●●

●●

●●

●●

●●

●●●●

●●

●●●

●●●●●

●●●●●●

●●

●●●●●

●●●●

●●●●●

●●●●

●●●●

●●●●●

●●

●●

●●●

●●●●

●●

●●●

●●●●●

●●●●

●●●

●●●●

●●

●●●●

● ●

●●

●●●

●●●●●

●●●

●●●●●

●●●●●

●●●●

●●

●●

●●●●

●●●●

●●●●

●●

●●

●●

●●●●●

●●●

●●●●●

●●●●●

●●

●●●●

●●●●●

●●

●●●

●●●●

●●●●●

● ● ● ●●

●●●●

●●●●

●●

●●●●●

●●●●●

●●●●●

●●

●●●●●

●●●●

●●

●●●

●●●●●

●●

●●

●●●●●

●●●●

● ●

●●

●●●●●

●●

●●●●

●●●●●●

●●●●●

●●●

●●●

●●●●

●●

●●●●

●●●●●

●●●●●

●●●●●●

●●●●

●●●●

●●●●

●●

●●

●●

●●●●●●

●●●●

●●●●●

●●●●●

●●●●●

●●●●

●●

●●●

●●●

●●

●●

●●●●

●●●●●●

●●●●

●●●●●

●●

●●

●●

●●

●●●●

●●●●●

●●●●

●●●●●●

●●●●

Figure 4. Predicted vs observed effect of combining PGDM1400 and PGT121

Loewe additivity Bliss independence

Predicted from individual parameters of PGDM1400 and PGT121 fits

Obs

erve

d fro

m a

dmin

iste

ring

PG

DM

1400

+ P

GT1

21

TwobNAbcombinaBons ThreebNAbcombinaBons

bNAb1 bNAb2IC80(80)(μg/mL) bNAb1 bNAb2 bNAb3

IC80(80)(μg/mL)

VRC07-523-LS CAP256-VRC26-25 0.856 VRC07-523-LS CAP256-VRC26-25 PGT121 0.483VRC07-523-LS PGDM1400 1.25 VRC07-523-LS CAP256-VRC26-25 10-1074 0.537VRC07-523-LS PGT121 1.81 3BNC117 CAP256-VRC26-25 PGT121 0.654VRC07-523-LS 10-1074 1.96 3BNC117 CAP256-VRC26-25 10-1074 0.726VRC07-523-LS 10E8 2.02 VRC07-523-LS PGDM1400 PGT121 0.726PGT121 CAP256-VRC26-25 2.10 VRC07-523-LS 10E8 CAP256-VRC26-25 0.7383BNC117 CAP256-VRC26-25 2.20 VRC07-523-LS PGDM1400 10-1074 0.807VRC07-523-LS PGT145 2.28 3BNC117 PGDM1400 PGT121 1.0310-1074 CAP256-VRC26-25 2.48 VRC07-523-LS 10E8 PGDM1400 1.04

Table 3. Predicted IC80(80) for selected two and three bNAb combinations

Concentration (µg/mL)

Inhi

bitio

n

*p<0.05, **p<0.01, ***p<0.001